Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Arcera and Fosun sign MoU for neuroscience innovation
  • M&A / Deals

Arcera and Fosun sign MoU for neuroscience innovation

Pharmaceutical Business Review

The initiative aligns with China's and the United Arab Emirates' (UAE) broader strategic objectives to enhance healthcare and the life sciences industry.

Neuroscience

Read full story

pharminent April 29, 2026 (Last updated: April 29, 2026)

Pharmaceutical Business Review

The initiative aligns with China’s and the United Arab Emirates’ (UAE) broader strategic objectives to enhance healthcare and the life sciences industry.

Neuroscience

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Rocket to sell PRV for $180m to advance gene therapy pipeline
Next: Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies

Related Stories

  • M&A / Deals

J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout

pharminent July 31, 2026
  • M&A / Deals

Eisai and CORE Biomedicine agree on global licence for oncology pipeline

pharminent July 29, 2026
  • M&A / Deals

Argenx signs agreement to buy Forte Biosciences for $2.2bn

pharminent July 28, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.